Biocon Limited is an Indian biopharmaceutical company based in Bangalore Within biopharmaceuticals, the Company manufactures generic active pharmaceutical ingredients that are sold in the developed markets of the United States and Europe. It also manufactures biosimilar Insulins, which are sold in India as branded formulations and in both bulk and formulation forms. In research services, Syngene International Limited is engaged in the business of custom research in drug discovery while the other fully owned subsidiary Clinigene International Limited is in the clinical development space. In December 2009, Biocon acquired the Active Pharma Ingredients undertaking from IDL Speciality Chemicals Ltd., a subsidiary of Gulf Oil Corporation Limited. Located with R & D in Bangalore and API unit in Hyderabad, India, Biocon has two subsidiaries— Syngene, a custom research organisation, and Clinigene, a clinical research organisation. Biocon’s presence straddles four main therapeutic areas—Diabetology, Cardiology, Nephrology and Oncology— and plans to introduce two new divisions, Comprehensive Care, and Immunotherapy, this year. Biocon’s cardiology, nephrology, diabetology and oncology products including BESTOR, BASALOGTM, BioMAb EGFR, STATIX, NUFIL safe, INSUGEN, TACROGRAF, ERYPRO safe, and MYOKINASE are claimed to be considerably less expensive than other leading brands. Two of its novel programs on the verge of proof-of-concept stage are IN-105, which is the only oral insulin in the world to be in long duration clinical trials, and the T1h, a novel humanised monoclonal antibody, the only first-in-class novel MAb being tested in India for rheumatoid arthritis and psoriasis.